Compare RAIL & RFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RAIL | RFL |
|---|---|---|
| Founded | 1901 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Railroads | Real Estate |
| Sector | Industrials | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 141.0M | 133.1M |
| IPO Year | 2005 | 2017 |
| Metric | RAIL | RFL |
|---|---|---|
| Price | $4.69 | $0.91 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $10.67 | N/A |
| AVG Volume (30 Days) | ★ 303.0K | 53.9K |
| Earning Date | 11-09-2026 | 12-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 134.94 | 44.23 |
| EPS | ★ 0.32 | N/A |
| Revenue | ★ $500,991,000.00 | $917,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $48.30 | N/A |
| P/E Ratio | $14.15 | ★ N/A |
| Revenue Growth | N/A | ★ 43.96 |
| 52 Week Low | $3.85 | $0.85 |
| 52 Week High | $14.90 | $3.96 |
| Indicator | RAIL | RFL |
|---|---|---|
| Relative Strength Index (RSI) | 43.74 | 30.19 |
| Support Level | $3.94 | N/A |
| Resistance Level | $5.48 | $1.38 |
| Average True Range (ATR) | 0.34 | 0.11 |
| MACD | 0.11 | 0.01 |
| Stochastic Oscillator | 43.64 | 22.86 |
FreightCar America Inc is a diversified manufacturer and supplier of railcars and railcar components. It designs and manufactures a variety of railcar types for transportation of bulk commodities and containerized freight products in North America. The company also provides railcar rebody and repair services, railcar conversion services, and supplies railcar parts. The company has two segments: Manufacturing and Aftermarket. The majority of the company's revenue is derived from the Manufacturing segment, which includes new railcar manufacturing, used railcar sales, and various conversions and rebodies. Geographically, it generates the maximum revenue from the United States.
Rafael Holdings Inc is a biotechnology firm that develops pharmaceuticals and invests in clinical and early-stage companies in pharmaceuticals and medical devices. Trappsol Cyclo is in Phase 3 trials for Niemann-Pick Disease Type C1. The company focuses on completing these trials, seeking regulatory approval, and commercializing the product. It also invests in portfolio companies including Cyclo, LipoMedix, Barer, Rafael Medical Devices, Cornerstone, and Day Three, targeting therapeutics for unmet medical needs. The business operates through three segments: Healthcare, Infusion Technology, and Real Estate. Operations are based in the United States and Israel.